Jefferies rates Vectura at buy

Jefferies & Co., Inc. analyst Robin Campbell rated Vectura Group at buy as the company delivers solid product development, especially drug delivery using dry powder inhalers. Recent deals for VR315 (in Europe) and the GyroHaler device should keep Vectura busy for the next 12 months, according to the analyst. Shares of the Wiltshire, U.K.-based pharmaceutical company were up 1.50p, or 1.63%, at 93.50p on volume of 14,515 shares versus the three-month running average of 478,196 shares. (London: VEC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.